Back to article: LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects


FIGURE 4: LTX-315 treatment causes CD8 T cell infiltration of melanoma and soft tissue sarcoma tumors in patients. (A) Representative hematoxylin and eosin (H&E) staining and immunohistochemistry for CD3+ and CD8+ cells (brown) on melanoma patient biopsy sections before and after LTX-315 treatment. (B) Quantification of CD3+ cells in melanoma biopsies, based on immunohistochemistry staining shown in (A). (C) Same analysis as shown in (B) for quantification of CD8+ cells. (D) Representative H&E staining and immunohistochemistry for CD3+ and CD8+ cells (brown) on patient biopsy sections of sarcomas before and after LTX-315 treatment. (E) Quantification of CD3+ cells in sarcoma biopsies, based on immunohistochemistry staining shown in (D). (F) Same analysis as shown in (E) for quantification of CD8+ cells.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.

Close